Search

Your search keyword '"Bulabois, C"' showing total 2 results
Start Over Author "Bulabois, C" Journal british journal of haematology
2 results on '"Bulabois, C"'

1. Efficacy of haematopoietic stem cell boost as a rescue for poor graft function after haematopoietic stem cell transplantation: A multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy ( SFGM‐TC )

Author

Gaffet, M., primary, Wiedemann, A., additional, Dalle, J.‐H., additional, Bilger, K., additional, Forcade, E., additional, Robin, M., additional, Cornillon, J., additional, Labussière‐Wallet, H., additional, Ceballos, P., additional, Bulabois, C.‐E., additional, Loschi, M., additional, Orvain, C., additional, Rubio, M. T., additional, Neven, B., additional, Pagliuca, S., additional, and Pochon, C., additional

Published
2023
Full Text
View/download PDF

2. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.

Author

Moreau P, Kergueris MF, Milpied N, Le Tortorec S, Mahé B, Bulabois CE, Rapp MJ, Larousse C, Bataille R, and Harousseau JL

Subjects
Adolescent, Adult, Combined Modality Therapy, Female, Hodgkin Disease drug therapy, Hodgkin Disease metabolism, Humans, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute metabolism, Lymphoma, Non-Hodgkin drug therapy, Lymphoma, Non-Hodgkin metabolism, Male, Melphalan adverse effects, Melphalan pharmacokinetics, Multiple Myeloma drug therapy, Multiple Myeloma metabolism, Pilot Projects, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation methods, Hodgkin Disease therapy, Leukemia, Myeloid, Acute therapy, Lymphoma, Non-Hodgkin therapy, Melphalan therapeutic use, Multiple Myeloma therapy
Abstract

We studied the pharmacokinetics and toxicity of 220 mg/m2 melphalan (HDM 220) followed by autologous stem cell transplantation in 16 patients with advanced haematological malignancies. Pharmacokinetic parameters (mean values of steady-state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half-life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports. HDM 220 was feasible. Extramedullary toxicity was mainly W.H.O. grade 4 mucositis (13/16 patients). The median duration of 41 d (10, not reached) of thrombocytopenia < 25 x 10(9)/l was long. In multiple myeloma the response rate was 89% in heavily pretreated patients, suggesting that HDM 220 could be considered earlier in the course of the disease as an alternative consolidation therapy.

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results